mRNA therapeutics manufacturing has been a major industrial talking point since its development during the COVID-19 pandemic. Now that CDMOs are developing the technologies and the capacities to scale it up, we find out just how much potential there is in this sector
CDMOs are developing the technologies and the capacities to scale mRNA therapeutics manufacturing. Eike Jöst discusses the potential successes in the sector.
Interviewee Biography
Eike Jöst, a principal scientist at Merck KGaA Darmstadt, Germany, is responsible for developing innovations in mRNA manufacturing as part of the company’s Life Science Service offering.
His introduction to the world of mRNA began at Würzburg University around ten years ago where he focused on optogenetics to engineer light responsive cells. This field gained momentum nearly 20 years ago by injecting mRNA into cells, which enabled them to express photoreceptor genes. Now he helps to facilitate the possibilities by providing mRNA manufacturing capabilities that could lead to new, previously unimaginable, treatments.